Evidence map›Paper›PMID 38590416›Full record

ArticleAmerican journal of cancer research2024

Risk factors for methotrexate resistance in low-risk gestational trophoblastic neoplasia patients (FIGO score 0-4).

Tianzhe Jin, Zijun Zhou, Mengmeng Lin, Shuo Yuan, Yite Xue, Taotao Yin, Ruiyi Xu, Bingxin Chen, Jianwei Zhang, Jiehao Sun and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Tianzhe JinZhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women's Hospital, Zhejiang University School of Medicine Hangzhou 310006, Zhejiang, China.
Zijun ZhouDepartment of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University Wenzhou 325000, Zhejiang, China.
Mengmeng LinDepartment of Gynecology, The First Affiliated Hospital of Wenzhou Medical University Wenzhou 325000, Zhejiang, China.
Shuo YuanZhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women's Hospital, Zhejiang University School of Medicine Hangzhou 310006, Zhejiang, China.
Yite XueZhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women's Hospital, Zhejiang University School of Medicine Hangzhou 310006, Zhejiang, China.
Taotao YinZhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women's Hospital, Zhejiang University School of Medicine Hangzhou 310006, Zhejiang, China.
Ruiyi XuZhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women's Hospital, Zhejiang University School of Medicine Hangzhou 310006, Zhejiang, China.
Bingxin ChenZhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women's Hospital, Zhejiang University School of Medicine Hangzhou 310006, Zhejiang, China.
Jianwei ZhangZhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women's Hospital, Zhejiang University School of Medicine Hangzhou 310006, Zhejiang, China.
Jiehao SunDepartment of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University Wenzhou 325000, Zhejiang, China.
Xiao LiDepartment of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine Hangzhou 310006, Zhejiang, China.
Yan HuDepartment of Gynecology, The First Affiliated Hospital of Wenzhou Medical University Wenzhou 325000, Zhejiang, China.
Lili ChenDepartment of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine Hangzhou 310006, Zhejiang, China.
Hui WangZhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women's Hospital, Zhejiang University School of Medicine Hangzhou 310006, Zhejiang, China.
Women's Hospital, School of Medicine, Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The challenge of methotrexate (MTX) resistance among low-risk gestational trophoblastic neoplasia (GTN) patients has always been prominent. Despite the International Federation of Gynaecology and Obstetrics (FIGO) score of 0-4 patients comprising the majority of low-risk GTN patients, a comprehensive exploration of the prevalence and risk factors associated with MTX resistance has been limited. Therefore, we aimed to identify associated risk factors in GTN patients with a FIGO score of 0-4. Between January 2005 and December 2020, 310 low-risk GTN patients received primary MTX chemotherapy in two hospitals, with 265 having a FIGO score of 0-4. In the FIGO 0-4 subgroup, 94 (35.5%) were resistant to MTX chemotherapy, and 34 (12.8%) needed multi-agent chemotherapy. Clinicopathologic diagnosis of postmolar choriocarcinoma (OR = 17.18, 95% CI: 4.64-63.70,

Indexed as

choriocarcinomadecision tree modelGestational trophoblastic neoplasiahuman chorionic gonadotropinmethotrexate resistance

Identifiers

PMID38590416
PMCPMC10998750
OpenAlexW4393985155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.